天津医药

• 论著 • 上一篇    下一篇

RhoB和E-cadherin在非小细胞肺癌组织中的表达及临床意义

谭祎媚1,张逊2,徐美林3,王菁4,徐医军2   

  1. 1. 天津医科大学
    2. 天津市胸科医院
    3. 天津市胸科医院病理科
    4. 天津胸科医院病理科
  • 收稿日期:2013-05-21 修回日期:2013-08-06 出版日期:2014-01-15 发布日期:2014-01-15
  • 通讯作者: 谭祎媚

The Expression and Clinical significance of RhoB and E-cadherin in Non-Small Cell Lung Cancer Tissues

  • Received:2013-05-21 Revised:2013-08-06 Published:2014-01-15 Online:2014-01-15

PDF (PC)

3232

摘要： 目的 探讨非小细胞肺癌 （NSCLC） 中RhoB和E-钙黏蛋白 （E-cadherin） 的表达及其临床意义。方法采用免疫组化Super Pic TureTMPolymer二步法， 检测116例NSCLC组织 （NSCLC组） 和同期116例正常余肺组织 （正常组） 中RhoB和E-cadherin的表达， 并分析其表达与患者临床病理特征及预后的关系。结果 NSCLC组RhoB、 E-cad?herin阳性表达率均低于正常组 （57.76% vs 87.07%， 54.31% vs 85.34%， 均P＜0.01）。NSCLC组织中RhoB的表达强度在不同肿瘤病理类型、 肿瘤分化程度及淋巴结转移情况间的差异有统计学意义， E-cadherin的表达强度在不同TNM分期、 肿瘤分化程度及淋巴结转移情况间的差异有统计学意义。NSCLC组RhoB与E-cadherin的表达呈正相关 （r=0.503， P＜0.01）。RhoB高表达的患者3年生存率高于低表达者 （83.93% vs 40.00%， Log-rank χ2=18.992， P < 0.01）； E-cadherin高表达的患者3年生存率高于低表达者 （85.11% vs 44.93%， Log-rank χ2=16.680， P < 0.01）。RhoB和E-cad?herin共同低表达、 淋巴结转移是影响NSCLC患者预后的危险因素。结论 RhoB与E-cadherin在NSCLC组织中的表达呈现较好的相关性， 检测二者的表达对判断NSCLC患者的临床病理学特征及预后有一定提示作用。

关键词: 癌, 非小细胞肺癌, 免疫组织化学, 预后, Kaplan-Meiers评估, RhoB, E-cadherin

Abstract: [Abstract] Objective To investigate expression of RhoB and E-cadherin in Non-Small Cell Lung Cancer(NSCLC) and their clinical significances. Methods Immunohistochemical staining was applied to detect expression of RhoB and E-cadherin in NSCLC group and control group. Correlations of expression of RhoB and E-cadherin to clinical pathological parameters and prognosis and their correlations were analysed. Results The expression intensities of RhoB and E-cadherin in NSCLC were distinctly lower than those in control group. The expression of RhoB and E-cadherin in NSCLC demonstrated significantly positive relation(r=0.503，P<0.01). The expression of RhoB in NSCLC was significantly different in pathological type, differentiation and lymph node metastasis(P <0.05 or P<0.01).The expression of E-cadherin in NSCLC was significantly different in TNM stage, differentiation and lymph node metastasis(P <0.05 or P<0.01). What’s more, the “coordinated expression” of RhoB and E-cadherin in NSCLC was significantly different in adenosquamous carcinoma, differentiation, TNM stage and lymph node metastasis(P <0.05 or P<0.01). The 3-year survival rates were higher in patients with RhoB high expression(83.93%) than those with low expression(40.00%), while the 3-year survival rates were higher in patients with E-cadherin high expression(85.11%) than those with low expression (44.93%). Further multivariate analysis suggested that both low expression of RhoB and E-cadherin and lymph node metastasis were prognostic indicators for NSCLC(P<0.001). Conclusion The expression of RhoB and E-cadherin shows a good correlation in NSCLC. Detecting the expression of RhoB combined with E-cadherin in NSCLC tissue may give a clue on prognosis of patient.

Key words: carcinoma, non-small-cell lung cancer, immunohistochemistry, prognosis, Kaplan-Meiers estimate, RhoB, E-cadherin